GRAL Share Price Performance
US$86.41
72.21 (508.52%)
52.9% overvalued intrinsic discount
US$56.50
Fair Value
Price US$86.41
AnalystConsensusTarget US$56.50
Fair ValueUS$56.50
Share PriceUS$86.41
52.9% overvalued intrinsic discount
GRAIL, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
GRAL Community Narratives
AN
Fair Value US$56.5 52.9% overvalued intrinsic discount
FDA Approval And NHS Studies Will Transform Cancer Detection
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
FDA Approval And NHS Studies Will Transform Cancer Detection
Key Takeaways Positive clinical results and expanding commercial adoption of Galleri position GRAIL for strong regulatory momentum, payer support, and accelerated, diversified revenue growth. Enhanced process scalability and disciplined cost control are improving margins and reducing losses, while global partnerships and demographic trends drive long-term opportunity.
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$56.5
52.9% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
20.22% p.a.
Profit Margin
16.11%
Future PE
80.58x
Share price in 2028
US$68.58
Snowflake Analysis
GRAIL, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -12.29
- -56.53%
- -329.86%
- 0%
About GRAL
- Founded
- 2015
- Employees
- 1000
- CEO
- WebsiteView website
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
